ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2344

Treatment Modes in Rheumatoid Arthritis: Moving Toward Shared Decision-Making

Peter C. Taylor1, Neil Betteridge2, T Michelle Brown3, John Woolcott4, Alan J. Kivitz5, Cristiano A F Zerbini6, Diane Whalley7, Oyebimpe Olayinka-Amao3, Connie Chen8, Palle Dahl9, Dario Ponce de Leon10, David Gruben11 and Lara Fallon12, 1University of Oxford, Oxford, United Kingdom, 2Neil Betteridge Associates, London, United Kingdom, 3RTI Health Solutions, Research Triangle Park, NC, 4Pfizer Inc, Collegeville, PA, 5Altoona Center for Clinical Research, Duncansville, PA, 6Centro Paulista de Investigação Clinica, São Paulo, Brazil, 7RTI Health Solutions, Manchester, United Kingdom, 8Pfizer Inc, New York, NY, 9Pfizer Inc, Ballerup, Denmark, 10Pfizer Inc, Lima, Peru, 11Pfizer Inc, Groton, CT, 12Pfizer Canada, Montreal, QC, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: DMARDs, patient preferences, rheumatoid arthritis (RA) and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Patient Outcomes, Preferences, and Attitudes Poster II: Patient Perspectives

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Treatment recommendations in RA emphasize shared decision-making,1 but little is known about patient (pt) perspectives. Through qualitative research, we aim to understand pt preferences for RA treatment modes of administration and reasons for these preferences, to help guide pt-physician shared decision-making.

Methods: Pt-reported demographic and disease activity information was obtained at screening alongside qualitative interviews conducted using a semi-structured interview guide among adult pts with RA in Brazil, France, Germany, Italy, Spain, Switzerland, UK, and US who were currently taking a DMARD (biologic or non-biologic, including a JAK inhibitor). A 100-point allocation task was used to evaluate the strength of preference (0–100; 100 = strongest) across 4 treatment modes: oral (OR; once daily), self-injection (SI; weekly), clinic-injection (CI; weekly), and infusion (INF; monthly). Transcripts were developed in English; ATLAS.ti software (v7.5) was used for qualitative coding and analysis.

Results: 100 interviews were conducted (female: 75.0%; mean age: 53.9 yrs; mean time since diagnosis: 11.6 yrs). Of the 98 pts who described the severity of their RA, most (70.4%) experienced moderate/severe RA. The most commonly reported symptoms were pain/ache (90.0%), swelling/inflammation (58.0%), and fatigue (54.0%). Current RA medication modes included OR (60.0%), injection (57.0%), and INF (14.0%); 79.0% and 37.0% of pts had experience with injection and INF medications, respectively.

Among the 4 treatment modes, OR was allocated the highest mean (standard deviation) preference points (47.3 [33.1]) and was ranked as 1st choice by the greatest percentage of pts (57.0%), followed by SI (29.7 [27.7]; 29.0%), INF (15.4 [24.6]; 16.0%), and CI (7.5 [14.1]; 2.0%). Notably, the percentage of pts with a 1st choice rank for OR was greater in the US vs Europe (73.3% vs 50.0%; p<0.05). Overall, 56.0% of pts had a ‘strong’ 1st choice preference (ie, point allocation ≥70); the majority of these pts chose OR (62.5%) vs SI (23.2%), INF (10.7%), or CI (3.6%). Speed/ease of administration was the most common reason for pts choosing OR or SI (Table; 52.6%, 55.2%). The most common reason for pts not choosing OR was not wanting to take another pill (37.2%), and for not choosing SI it was to avoid pain due to needles (46.5%).

Conclusion: These data show the most important issues to pts regarding mode of administration of RA medication. Most pts preferred OR as an RA treatment mode, followed by SI. Rationales for preference included ease of use, safety concerns, dosing frequency, feelings of control, and avoidance of pain and needles. While 56.0% of pts had a strong preference for their 1st choice, nearly half did not and may be receptive to, and benefit from, discussions with their healthcare professional and/or pt support groups about RA treatment mode options to guide shared decision-making.

1. Singh JA et al. Arthritis Rheumatol 2016; 68: 1-26.



Disclosure: P. C. Taylor, Eli Lilly, Galapagos, UCB, 2,AbbVie, Eli Lilly, Galapagos, Pfizer Inc, 5; N. Betteridge, Amgen, Eli Lilly, Grunenthal, Pfizer Inc, Roche, Sanofi, 5,International Liaison Officer (EULAR), 6; T. M. Brown, None; J. Woolcott, Pfizer Inc, 1,Pfizer Inc, 3; A. J. Kivitz, Novartis, 1,AbbVie, Boehringer Ingelheim, Flexion, Genzyme, Janssen, Pfizer Inc, Regeneron, Sanofi, SUN Pharma, UCB, 5,Celgene, Flexion, Genetech, Genzyme, Horizon, Ironwood, Merck, Novartis, Pfizer Inc, Regeneron, Sanofi, 8,Altoona Center for Clinical Research, 9; C. A. F. Zerbini, Amgen, Biogen, Eli Lilly, Merck, Novartis, Pfizer Inc, Sanofi, 2,Amgen, Eli Lilly, Pfizer Inc, Sanofi, 8; D. Whalley, RTI Health Solutions, 3; O. Olayinka-Amao, None; C. Chen, Pfizer Inc, 1,Pfizer Inc, 3; P. Dahl, Pfizer Inc, 1,Pfizer Inc, 3; D. Ponce de Leon, Pfizer Inc, 1,Pfizer Inc, 3; D. Gruben, Pfizer Inc, 1,Pfizer Inc, 3; L. Fallon, Pfizer Inc, 1,Pfizer Inc, 3.

To cite this abstract in AMA style:

Taylor PC, Betteridge N, Brown TM, Woolcott J, Kivitz AJ, Zerbini CAF, Whalley D, Olayinka-Amao O, Chen C, Dahl P, Ponce de Leon D, Gruben D, Fallon L. Treatment Modes in Rheumatoid Arthritis: Moving Toward Shared Decision-Making [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/treatment-modes-in-rheumatoid-arthritis-moving-toward-shared-decision-making/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-modes-in-rheumatoid-arthritis-moving-toward-shared-decision-making/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology